%0 Journal Article
%A Jansen, Lina
%A Boakye, Daniel
%A Alwers, Elizabeth
%A Carr, Prudence R
%A Reissfelder, Christoph
%A Schneider, Martin
%A Martens, Uwe M
%A Chang-Claude, Jenny
%A Hoffmeister, Michael
%A Brenner, Hermann
%T Uptake Rates of Novel Therapies and Survival Among Privately Insured Versus Publicly Insured Patients With Colorectal Cancer in Germany.
%J Journal of the National Comprehensive Cancer Network
%V 19
%N 4
%@ 1540-1405
%C Cold Spring Harbor, NY
%I Harborside Press
%M DKFZ-2021-00350
%P 411-420
%D 2021
%Z #EA:C070#LA:C070# / 19(4):411-420
%X In the era of personalized medicine, cancer care is subject to major changes and innovations. It is unclear, however, to what extent implementation of such innovations and their impact on patient outcomes differ by health insurance type. This study compared provision of treatment and survival outcomes among patients with colorectal cancer (CRC) who had statutory health insurance (SHI) versus private health insurance (PHI) in Germany.We analyzed patterns of CRC treatment (surgery, chemotherapy/radiotherapy, and targeted therapy) and survival in a large cohort of patients who were diagnosed with CRC in 2003 through 2014 and were observed for an average of 6 years. Associations of type of health insurance with treatment administration and with overall, CRC-specific, and recurrence-free survival were investigated using multivariable logistic and Cox proportional hazards models, respectively.Of 3,977 patients with CRC, 427 (11
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33578373
%R 10.6004/jnccn.2020.7636.
%U https://inrepo02.dkfz.de/record/167446